First clinical application of cord blood mesenchymal stromal cells in children with multi-drug resistant nephrotic syndrome.

ABSTRACT:

Background and objectives

Children with multi-drug resistant idiopathic nephrotic syndrome (MDR-INS) usually progress to end-stage kidney disease with a consistent risk of disease recurrence after transplantation. New therapeutic options are needed for these patients. Mesenchymal stromal cells (MSCs) are multipotential non-hematopoietic cells with several immunomodulatory properties and growing clinical applications. Cord blood-derived MSC have peculiar anti-inflammatory and immunosuppressive properties. We aimed at assessing safety and efficacy of cord-blood-derived MSCs (CB-MSCs) in children with MDR-INS.

Design, setting, participants

Prospective, open-label, single arm phase I-II pilot study. Pediatric patients with MDR-INS, resistant to at least two lines of therapy, wer

SUBMITTER: Morello W 

PROVIDER: S-EPMC9389735 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature